Device therapy in hypertrophic cardiomyopathy.
With increasing awareness of the condition and particular attention being paid to family screening, the number of patients being diagnosed with hypertrophic cardiomyopathy is increasing. Although the majority of patients remain at low risk for sudden cardiac death, all patients need to undergo rigorous and ongoing risk factor stratification in order to best identify those at high risk. Although implantable cardioverter-defibrillators have proven to be effective in the prevention of sudden cardiac death, careful consideration of device implantation in high-risk patients is necessary in view of the potential for device complications and their impact on quality of life.
University of Aberdeen, Aberdeen, AB25 2ZD, UK. rogerbeadle@hotmail.com
Roger
R
Beadle
Lynne
L
Williams
D000328:Adult; D001145:Arrhythmias, Cardiac / Q000209:etiology / Q000503:physiopathology; D002304:Cardiac Pacing, Artificial / Q000379:methods; D002312:Cardiomyopathy, Hypertrophic / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D024741:Cardiomyopathy, Hypertrophic, Familial / Q000150:complications / Q000503:physiopathology / Q000628:therapy; D016757:Death, Sudden, Cardiac / Q000209:etiology; D017147:Defibrillators, Implantable / Q000009:adverse effects; D006801:Humans; D018570:Risk Assessment; D012307:Risk Factors; D055815:Young Adult